Bliss GVS Pharma Limited has announced that ICRA Limited has assigned credit ratings to the company's banking facilities worth Rs. 100.00 crore. The pharmaceutical company informed both the National Stock Exchange and BSE Limited about this development on April 08, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Credit Rating Details

ICRA Limited has assigned the following ratings to Bliss GVS Pharma's banking facilities:

The rating assignment was communicated through ICRA's letter dated April 08, 2026, bearing reference number ICRA/Bliss GVS Pharma Limited/08042026/1. The rating covers facilities provided by Federal Bank Limited and was assigned on April 07, 2026.

Rating Surveillance and Terms

According to ICRA's communication, the assigned ratings will become due for surveillance within one year from the date of the rating communication letter. The rating agency has reserved the right to review and revise the ratings at any time based on new information becoming available or other circumstances that could impact the ratings.

The ratings are specific to the current terms and conditions of the instruments as indicated by the company. Any changes in the terms, conditions, or size of the rated instruments would require a review by ICRA. The company is required to inform ICRA about any defaults, delays in repayment, or significant developments that could impact debt servicing capability.

Regulatory Compliance

Bliss GVS Pharma's Company Secretary Aditi Bhatt signed the regulatory filing, ensuring compliance with stock exchange listing requirements. The company has provided complete documentation including ICRA's rating letter to both NSE and BSE for their records.

The rating assignment provides the company with formal credit assessment for its banking facilities, which supports its financial operations and lending arrangements with Federal Bank Limited.

Bliss GVS Pharma Limited has announced a significant extension of its special window facility for shareholders seeking to re-lodge transfer requests for physical shares. The pharmaceutical company published this intimation in newspapers on April 04, 2026, in compliance with regulatory requirements.

Extension Details and Timeline

Following SEBI circular HO/38/13/11(2)2026-MIRSD-POD/3750/2026 dated January 30, 2026, the company has extended the special window facility that was previously available from July 07, 2025, to January 06, 2026. The new extended window provides shareholders with a fresh one-year period from February 05, 2026, to February 04, 2027.

Eligibility and Requirements

This facility is exclusively available for transfer deeds that were lodged before April 01, 2019, but were subsequently rejected, returned, or not attended to due to deficiencies in documents, processes, or other issues. Shareholders must ensure they have complete documentation when re-lodging their requests.

Important requirements include:

• Shares re-lodged during this period will be transferred only in demat mode
• Shareholders must have an active demat account
• Client Master List (CML) must be provided along with transfer documents

Contact Information and Process

Eligible shareholders can contact the company's Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime India Private Limited), at their office located at C-101, 247 Park, LBS Marg, Vikhroli West, Mumbai, Maharashtra-400083.

Regulatory Compliance

The newspaper publication was made in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published in 'The Economic Times & The Free Press Journal' (English dailies) and 'Maharashtra Times & Navshakti' (regional dailies) on April 04, 2026.

The company has emphasized that eligible shareholders should submit their transfer requests duly completed in all respects on or before the SEBI deadline of February 04, 2027. This extension provides shareholders with additional time to complete the necessary documentation and processes for transferring their physical shares to demat mode.